Investigational drug · Phase 3
KC1036
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Ewing Sarcoma, Esophageal Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma (ESCC).
Phase 3Last checked: Nov 19, 2026Latest source record: Mar 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
7
Any phase or sponsor naming "KC1036"
First trial start
2024
Feb 5, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "KC1036", any sponsor or status.
Conditions studied
As listed on its trial records.
- Ewing Sarcoma
- Esophageal Squamous Cell Carcinoma
- Esophageal Squamous Cell Carcinoma (ESCC)
Approved drugs for the same conditions: Stomach and esophageal cancer · Sarcoma · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "KC1036" as an intervention, largest first.
- A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal CancerPivotal-lookingRecruiting
Beijing Konruns Pharmaceutical Co., Ltd.Industry
NCT06194734 · 490 participants (planned) · Start Feb 5, 2024 · Primary completion Dec 30, 2026
Drug: KC1036; Irinotecan and 2 more · For: Esophageal Squamous Cell Carcinoma
Sites: Beijing, China
- A Study of KC1036 in Patients with Advanced Solid TumorsStatus unknown
Beijing Konruns Pharmaceutical Co., Ltd.Industry
NCT04387916 · 207 participants (planned) · Start Sep 4, 2020 · Primary completion Oct 31, 2025
Drug: KC1036 · For: Advanced Solid Tumors
Sites: Chongqing, China; Haikou, China; Chengdu, China
Beijing Konruns Pharmaceutical Co., Ltd.Industry
NCT05260385 · 133 participants (planned) · Start Jan 24, 2022 · Primary completion Oct 30, 2025
Drug: KC1036 · For: Digestive System Tumors
Sites: Beijing, China; Bengbu, China; Chongqing, China · 13 sites in all
Beijing Konruns Pharmaceutical Co., Ltd.Industry
NCT07481058 · 60 participants (planned) · Start Dec 12, 2025 · Primary completion Dec 2027
Drug: KC1036; Toripalimab and 3 more · For: Esophageal Squamous Cell Carcinoma (ESCC)
Sites: Beijing, China
Beijing Konruns Pharmaceutical Co., Ltd.Industry
NCT05683886 · 30 participants (planned) · Start Feb 22, 2023 · Primary completion Feb 2025
Drug: KC1036 · For: Thymic Tumors
Sites: Shanghai, China; Chengdu, China
Beijing Konruns Pharmaceutical Co., Ltd.Industry
NCT06564272 · 30 participants (planned) · Start Sep 27, 2024 · Primary completion Apr 1, 2027
Drug: KC1036 · For: Ewing Sarcoma
Sites: Beijing, China
Beijing Konruns Pharmaceutical Co., Ltd.Industry
NCT05265338 · 12 participants · Start Mar 10, 2022 · Primary completion Mar 23, 2022
Drug: KC1036 · For: Healthy Subjects
Sites: Chengdu, China
Newest research
PubMed records naming it or its code names, newest first.
- KC1036 in ewing sarcoma: mechanistic insights and future directions for a multi-targeted therapeutic strategy.
Yang DJ, Yang L, Yang J, et al. · Angiogenesis 2025
- KC1036, a multi-kinase inhibitor with anti-angiogenic activity, can effectively suppress the tumor growth of Ewing sarcoma.
Ou X, Gao G, Ma Q, et al. · Angiogenesis 2025
Also in development for Ewing Sarcoma
- MK-2140Zilovertamab Vedotin, VLS-101Phase 39 trials
Merck & Co. · Diffuse Large B-Cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, B-cell Acute Lymphoblastic Leukemia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.